This message was sent to the AIM, Health Systems, LHD Health Officers, LHD Medical Directors, INE, IAP, MACI, MACI 2, PH Imms Leads, Imms All Staff, MSMS, and DSO All Staff listservs. Apologies for any duplication.

Hello Immunization Partners,

Please share the following information with providers in your jurisdiction.

On December 12, 2024, the Centers for Disease Control and Prevention (CDC) published an MMWR entitled New Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, October 2024.

On October 24, 2024, the Advisory Committee on Immunization Practices (ACIP) updated its recommendations for MenB-4C (Bexsero, GlaxoSmithKline) vaccine to align the dosing interval and schedule with the new Food and Drug Administration (FDA) label and harmonize with recommendations for MenB-FHbp (Trumenba, Pfizer, Inc.) vaccine. ACIP now recommends MenB-4C as a 2-dose series with doses administered at intervals of 0 and 6 months for healthy adolescents and young adults aged 16–23 years based on shared clinical decision-making and as a 3-dose series with doses administered at 0, 1–2, and 6 months for persons aged ≥10 years at increased risk.

The new MenB-4C dosing interval and schedule improves immune protection. ACIP recommendations for the MenB-4C dosing interval and schedule are now aligned with the updated FDA label and are harmonized with ACIP recommendations for use of MenB-FHbp.

These recommendations apply to use of the 2-dose and 3-dose schedules of MenB-4C and supersede previous ACIP recommendations for use of MenB-4C published in 2020.  Recommendations regarding use of MenB-FHbp and MenACWY-TT/MenB-FHbp (PENBRAYA, Pfizer), as well as recommendations for booster doses, are unchanged.

1. Adolescents and Young Adults Aged 16–23 Years (Shared Clinical Decision-Making Recommendation)
   • ACIP recommends that MenB-4C be administered to healthy adolescents and young adults aged 16–23 years as a 2-dose series at 0 and 6 months for the prevention of serogroup B meningococcal disease, based on shared clinical decision-making (Box). Shared clinical decision-making recommendations are not recommended for everyone in an age or risk group but are individually based and guided by a decision process between the health care provider and the patient or the patient’s parent or guardian.
2. Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease
   • ACIP recommends that MenB-4C be administered as a 3-dose series at 0, 1–2, and 6 months to persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease (i.e., persons with anatomic or functional asplenia, complement component deficiencies, or complement inhibitor use; microbiologists routinely exposed to meningitidis isolates; and persons at increased risk during an outbreak).

Thank you for all you do!
Your Immunization Outreach and Education Team,
Alyssa, Andrea, Dianne, Heidi, Lisa, and Sarah